Dose-related use of nonsteroidal anti-inflammatory drugs (NSAIDs) together with tumor necrosis factor inhibitors (TNFi) in ankylosing spondylitis (AS) patients have a synergistic effect in slowing radiographic progression. The greatest effect is seen in those using both high-dose NSAIDs and TNFi.
Dr. Lianne Gensler (University of California, San Francisco, US) told the audience that the potential of TNFi and/or NSAIDs to reduce radiographic progression in AS is uncertain. Until now, causal effects of both exposures on radiographic progression have not been convincingly demonstrated. In addition, no study has evaluated whether effects are comparable among different NSAIDs in this setting. Therefore, Gensler et al. explored the causal effects of TNFi on radiographic progression in AS and determined whether the NSAID dose and type impact this relationship.
A total of 519 adult patients from the Prospective Study of Outcomes in Ankylosing Spondylitis (PSOAS) cohort who met the modified New York criteria were included with at least 4 years of clinical and radiographic follow-up. Clinical and medication data were collected every 6 months and radiographs were performed at baseline and every 2 years. Longitudinal targeted maximum likelihood estimation was used to estimate the causal effect of TNFi and NSAIDs (using the NSAID index) on radiographic progression as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) at 2 and 4 years, accounting for time-varying covariates. The researchers adjusted for sex, race/ethnicity, education, disease duration, enrolment year, number of years on TNFi, and disease duration at time of TNFi start, NSAID use, TNFi use, days since last mSASSS measurement, Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP), smoking status, and missed visit status. The majority of patients were male (75%) and Caucasian (81%); the baseline mean age was 41.4 years and symptom duration was 16.8 years. Baseline mean mSASSS was 14.2. At baseline, 70% of patients used NSAIDs, TNFi were used by 46% of patients at baseline, and 15% used DMARDs.
Patients using TNFi and high-dose NSAIDs showed less progression at 4 years, with the least progression observed at both 2 and 4 years in those using TNFi + celecoxib. Celecoxib users had a higher NSAID index in comparison to other NSAID users and after controlling for NSAID dose, no change in mSASSS difference was seen. Gensler added: “It seems that celecoxib use, and not the dose of celecoxib, confers benefit in the setting of TNFi.” She concluded by saying that TNFi had shown to prevent radiographic progression in AS patients: “This was especially evident when patients were also exposed to NSAIDs at a higher dose at 4 years and with a greater effect in the setting of celecoxoib at 2 and 4 years. TNFi and NSAIDs may give a synergistic effect.” However, Gensler warned that despite the statistical approach taken in this trial, which addresses many of the biases in observational research, unmeasured confounders are still a possibility. It may be the case that celecoxib users on TNFi are different vs a celecoxib drug-specific effect with TNFi (See 1).
Sources:
Gensler LS, et al. Combined effects of tumor necrosis factor inhibitors and NSAIDs on radiographic progression in ankylosing spondylitis Abstract OP0198. EULAR 2018.